أخبار المنتجات
22 Aug 2022

GEA therefore developed a digital, continuous real-time monitoring system for production processes in the biopharmaceutical industry, the GEA BUCK® Digital Canary, for its customers. (Photo: GEA)
The patented innovation comprises a sensor that provides a constant reading (compared with a baseline) of any dust exposure at the sampling point. Adjustable to suit a specific particle size distribution if required, the information is relayed to a control system that initiates an alarm or corrective action if out-of-specification data is received.
Modern pharmaceutical equipment is designed to operate in a completely dust-tight manner; but it’s absolutely critical to be fully prepared for worst-case scenarios, such as an unexpected containment breach. As the level of potentially dangerous airborne particles is often far below what can be seen with the naked eye, the GEA BUCK® Digital Canary is designed to be a fully integrated part of your production line.
As soon as the sensor detects powder levels that are above the allowed limit, a warning is sent to the operators allowing them to leave the contaminated area as soon as possible. Once the concentration of airborne particles has returned to an acceptable level, the system will inform the operators that it’s safe.
Compatible with a wide range of new and existing solid dosage applications, the GEA BUCK® Digital Canary reduces the need for industrial hygiene testing, provides an audit trail in terms of cross-contamination risk and regulatory compliance, and can provide the trigger for preventive maintenance activities — potentially reducing the need for secondary personal protection equipment (PPE) — by offering real-time containment monitoring.
Downtime is costly. Product loss and/or exposing personnel to toxic or highly potent dust could be catastrophic. The GEA BUCK® Digital Canary is designed to prevent this.
Dr. Michael Golek
Media Relations
GEA Group Aktiengesellschaft
Ulmenstrasse 99
40476
Düsseldorf
Germany
+49 211 9136-0
GEA is one of the world’s largest suppliers of systems and components to the food, beverage and pharmaceutical industries.
The international technology group, founded in 1881, focuses on machinery and plants, as well as advanced process technology, components and comprehensive services. For instance, every second pharma separator for essential healthcare products such as vaccines or novel biopharmaceuticals is produced by GEA. In food, every fourth package of pasta or every third chicken nugget are processed with GEA technology.
With more than 18,000 employees, the group generated sales of about EUR 5.5 billion in more than 150 countries in the 2025 fiscal year. GEA plants, processes, components and services enhance the efficiency and sustainability of customers’ production. They contribute significantly to the reduction of CO2 emissions, plastic usage and food waste. In doing so, GEA makes a key contribution toward a sustainable future, in line with the company’s purpose: ”Engineering for a better world.”
GEA is listed on the German MDAX, the European STOXX® Europe 600 Index and is also a constituent of the leading sustainability indices DAX 50 ESG, MSCI Global Sustainability and Dow Jones Best-in-Class World.